{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:24:23Z","timestamp":1793823863345,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773763"],"award-info":[{"award-number":["81773763"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81521005"],"award-info":[{"award-number":["81521005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773763"],"award-info":[{"award-number":["81773763"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81521005"],"award-info":[{"award-number":["81521005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Histone deacetylase (HDAC) is a kind of protease that modifies histone to regulate gene expression, and is usually abnormally activated in tumors. The approved pan-HDAC inhibitors have demonstrated clinical benefits for patients in some hematologic malignancies. Only limited therapeutic success in breast cancer has been observed in clinical trials. In this study, we declare that pan-HDAC inhibitors targeting NEDD9-FAK pathway exacerbate breast cancer metastasis in preclinical models, which may severely impede their clinical success. NEDD9 is not an oncogene, however, it has been demonstrated recently that there are high level or activity changes of NEDD9 in a variety of cancer, including leukemia, colon cancer, and breast cancer. Mechanistically, pan-HDAC inhibitors enhance H3K9 acetylation at the nedd9 gene promoter via inhibition of HDAC4 activity, thus increase NEDD9 expression, and then activate FAK phosphorylation. The realization that pan-HDAC inhibitors can alter the natural history of breast cancer by increasing invasion warrants clinical attention. In addition, although NEDD9 has been reported to have a hand in breast cancer metastasis, it has not received much attention, and no therapeutic strategies have been developed. Notably, we demonstrate that FAK inhibitors can reverse breast cancer metastasis induced by upregulation of NEDD9 via pan-HDAC inhibitors, which may offer a potential combination therapy for breast cancer.<\/jats:p>","DOI":"10.1038\/s41392-022-01221-6","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T20:17:03Z","timestamp":1672949823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression"],"prefix":"10.1038","volume":"8","author":[{"given":"Zonglong","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-4956","authenticated-orcid":false,"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"1221_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bioorg.2016.05.005","volume":"67","author":"M Manal","year":"2016","unstructured":"Manal, M., Chandrasekar, M. J., Gomathi Priya, J. & Nanjan, M. J. Inhibitors of histone deacetylase as antitumor agents: a critical review. Bioorg. Chem. 67, 18\u201342 (2016).","journal-title":"Bioorg. Chem."},{"key":"1221_CR2","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.2174\/1568026619666181210152115","volume":"18","author":"Y Sun","year":"2018","unstructured":"Sun, Y. et al. Histone deacetylase inhibitors in cancer therapy. Curr. Top. Med. Chem. 18, 2420\u20132428 (2018).","journal-title":"Curr. Top. Med. Chem."},{"key":"1221_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1586\/17474086.2015.983065","volume":"8","author":"EN Libby","year":"2015","unstructured":"Libby, E. N. et al. Panobinostat: a review of trial results and future prospects in multiple myeloma. Expert Rev. Hematol. 8, 9\u201318 (2015).","journal-title":"Expert Rev. Hematol."},{"key":"1221_CR4","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","volume":"21","author":"JP Laubach","year":"2015","unstructured":"Laubach, J. P., Moreau, P., San-Miguel, J. F. & Richardson, P. G. Panobinostat for the treatment of multiple myeloma. Clin. Cancer Res 21, 4767\u20134773 (2015).","journal-title":"Clin. Cancer Res"},{"key":"1221_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/CAD.0000000000000040","volume":"25","author":"M Slingerland","year":"2014","unstructured":"Slingerland, M., Guchelaar, H. J. & Gelderblom, H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs 25, 140\u2013149 (2014).","journal-title":"Anticancer Drugs"},{"key":"1221_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.molonc.2010.11.003","volume":"5","author":"A Prat","year":"2011","unstructured":"Prat, A. & Perou, C. M. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 5, 5\u201323 (2011).","journal-title":"Mol. Oncol."},{"key":"1221_CR7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMra0801289","volume":"360","author":"C Sotiriou","year":"2009","unstructured":"Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790\u2013800 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1221_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s12253-018-0433-5","volume":"24","author":"P Guo","year":"2018","unstructured":"Guo, P. et al. The histone acetylation modifications of breast cancer and their therapeutic implications. Pathol. Oncol. Res. 24, 807\u2013813 (2018).","journal-title":"Pathol. Oncol. Res."},{"key":"1221_CR9","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/mc.22402","volume":"55","author":"E Contreras-Leal","year":"2016","unstructured":"Contreras-Leal, E. et al. Histone deacetylase inhibitors promote the expression of ATP2A3 gene in breast cancer cell lines. Mol. Carcinog. 55, 1477\u20131485 (2016).","journal-title":"Mol. Carcinog."},{"key":"1221_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.4161\/cbt.25088","volume":"14","author":"N Chatterjee","year":"2013","unstructured":"Chatterjee, N. et al. Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells. Cancer Biol. Ther. 14, 658\u2013671 (2013).","journal-title":"Cancer Biol. Ther."},{"key":"1221_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12858-014-0030-5","volume":"16","author":"L Li","year":"2015","unstructured":"Li, L. et al. Histone deacetylase inhibitor sodium butyrate suppresses DNA double strand break repair induced by etoposide more effectively in MCF-7 cells than in HEK293 cells. BMC Biochem 16, 2 (2015).","journal-title":"BMC Biochem"},{"key":"1221_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2015.04.086","volume":"567","author":"E Shagisultanova","year":"2015","unstructured":"Shagisultanova, E. et al. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. Gene 567, 1\u201311 (2015).","journal-title":"Gene"},{"key":"1221_CR13","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.3390\/cancers14102517","volume":"14","author":"M Tikhomirova","year":"2022","unstructured":"Tikhomirova, M. et al. NEDD9 restrains dsDNA damage response during non-small cell lung cancer (NSCLC) progression. Cancers (Basel) 14, 2517 (2022).","journal-title":"Cancers (Basel)"},{"key":"1221_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/1541-7786.MCR-13-0300","volume":"12","author":"SL McLaughlin","year":"2014","unstructured":"McLaughlin, S. L. et al. NEDD9 depletion leads to MMP14 inactivation by TIMP2 and prevents invasion and metastasis. Mol. Cancer Res. 12, 69\u201381 (2014).","journal-title":"Mol. Cancer Res."},{"key":"1221_CR15","doi-asserted-by":"publisher","first-page":"5751","DOI":"10.2147\/OTT.S113768","volume":"9","author":"P Li","year":"2016","unstructured":"Li, P. et al. The expressions of NEDD9 and E-cadherin correlate with metastasis and poor prognosis in triple-negative breast cancer patients. Onco Targets Ther. 9, 5751\u20135759 (2016).","journal-title":"Onco Targets Ther."},{"key":"1221_CR16","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41388-018-0463-1","volume":"38","author":"W Yu","year":"2019","unstructured":"Yu, W. et al. Estrogen receptor \u03b2 promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1\/miR-145-5p\/NEDD9 signals in lung cancer. Oncogene 38, 1225\u20131238 (2019).","journal-title":"Oncogene"},{"key":"1221_CR17","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1002\/jcp.29099","volume":"235","author":"J Chang","year":"2020","unstructured":"Chang, J. et al. miR-363-3p inhibits migration, invasion, and epithelial-mesenchymal transition by targeting NEDD9 and SOX4 in non-small-cell lung cancer. J. Cell. Physiol. 235, 1808\u20131820 (2020).","journal-title":"J. Cell. Physiol."},{"key":"1221_CR18","doi-asserted-by":"publisher","first-page":"25503","DOI":"10.18632\/oncotarget.25347","volume":"9","author":"S Grauzam","year":"2018","unstructured":"Grauzam, S. et al. NEDD9 stimulated MMP9 secretion is required for invadopodia formation in oral squamous cell carcinoma. Oncotarget 9, 25503\u201325516 (2018).","journal-title":"Oncotarget"},{"key":"1221_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09603-3","volume":"22","author":"J Zhou","year":"2022","unstructured":"Zhou, J. et al. miR-107 is involved in the regulation of NEDD9-mediated invasion and metastasis in breast cancer. BMC Cancer 22, 533 (2022).","journal-title":"BMC Cancer"},{"key":"1221_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10549-014-2979-6","volume":"145","author":"LV Rhodes","year":"2014","unstructured":"Rhodes, L. V. et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res. Treat. 145, 593\u2013604 (2014).","journal-title":"Breast Cancer Res. Treat."},{"key":"1221_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.tcb.2006.07.004","volume":"16","author":"WH Ziegler","year":"2006","unstructured":"Ziegler, W. H., Liddington, R. C. & Critchley, D. R. The structure and regulation of vinculin. Trends Cell Biol. 16, 453\u2013460 (2006).","journal-title":"Trends Cell Biol."},{"key":"1221_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nature03799","volume":"436","author":"AJ Minn","year":"2005","unstructured":"Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518\u2013524 (2005).","journal-title":"Nature"},{"key":"1221_CR23","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1091\/mbc.e07-09-0953","volume":"19","author":"MK Singh","year":"2008","unstructured":"Singh, M. K. et al. A novel Cas family member, HEPL, regulates FAK and cell spreading. Mol. Biol. Cell. 19, 1627\u20131636 (2008).","journal-title":"Mol. Biol. Cell."},{"key":"1221_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2222","volume":"11","author":"XJ Ma","year":"2009","unstructured":"Ma, X. J. et al. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 11, R7 (2009).","journal-title":"Breast Cancer Res"},{"key":"1221_CR25","doi-asserted-by":"publisher","first-page":"e74594","DOI":"10.1371\/journal.pone.0074594","volume":"8","author":"N Sima","year":"2013","unstructured":"Sima, N. et al. The overexpression of scaffolding protein NEDD9 promotes migration and invasion in cervical cancer via tyrosine phosphorylated FAK and SRC. PLoS One 8, e74594 (2013).","journal-title":"PLoS One"},{"key":"1221_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.9","volume":"4","author":"JE Bolden","year":"2013","unstructured":"Bolden, J. E. et al. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis. 4, e519 (2013).","journal-title":"Cell Death Dis."},{"key":"1221_CR27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769\u2013784 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1221_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1615\/CritRevOncog.2014012423","volume":"20","author":"A Turtoi","year":"2015","unstructured":"Turtoi, A., Peixoto, P., Castronovo, V. & Bellahc\u00e8ne, A. Histone deacetylases and cancer-associated angiogenesis: current understanding of the biology and clinical perspectives. Crit. Rev. Oncog. 20, 119\u2013137 (2015).","journal-title":"Crit. Rev. Oncog."},{"key":"1221_CR29","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/sj.jid.5701216","volume":"128","author":"T Murakami","year":"2008","unstructured":"Murakami, T. et al. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J. Invest. Dermatol. 128, 1506\u20131516 (2008).","journal-title":"J. Invest. Dermatol."},{"key":"1221_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CMR.0b013e328364c0ed","volume":"23","author":"DM Woods","year":"2013","unstructured":"Woods, D. M. et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res 23, 341\u2013348 (2013).","journal-title":"Melanoma Res"},{"key":"1221_CR31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/13543784.2017.1386172","volume":"26","author":"P Fedele","year":"2017","unstructured":"Fedele, P., Orlando, L. & Cinieri, S. Targeting triple negative breast cancer with histone deacetylase inhibitors. Expert Opin. Investig. Drugs 26, 1199\u20131206 (2017).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1221_CR32","doi-asserted-by":"publisher","first-page":"7138","DOI":"10.1158\/1078-0432.CCR-08-0122","volume":"14","author":"TH Luu","year":"2008","unstructured":"Luu, T. H. et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin. Cancer Res 14, 7138\u20137142 (2008).","journal-title":"Clin. Cancer Res"},{"key":"1221_CR33","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M G\u00f6ttlicher","year":"2001","unstructured":"G\u00f6ttlicher, M. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969\u20136978 (2001).","journal-title":"EMBO J."},{"key":"1221_CR34","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1158\/1535-7163.MCT-09-0717","volume":"9","author":"HW Jeon","year":"2010","unstructured":"Jeon, H. W. & Lee, Y. M. Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. Mol. Cancer Ther. 9, 1361\u20131370 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"1221_CR35","first-page":"3069","volume":"63","author":"LT Liu","year":"2003","unstructured":"Liu, L. T., Chang, H. C., Chiang, L. C. & Hung, W. C. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 63, 3069\u20133072 (2003).","journal-title":"Cancer Res."},{"key":"1221_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2693-3","volume":"16","author":"M D\u00edaz-N\u00fa\u00f1ez","year":"2016","unstructured":"D\u00edaz-N\u00fa\u00f1ez, M. et al. Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity. BMC Cancer 16, 667 (2016).","journal-title":"BMC Cancer"},{"key":"1221_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/19336918.2015.1112486","volume":"9","author":"J Feng","year":"2015","unstructured":"Feng, J. et al. Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail. Cell Adh Migr. 9, 495\u2013501 (2015).","journal-title":"Cell Adh Migr."},{"key":"1221_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2018.01.068","volume":"420","author":"W Xu","year":"2018","unstructured":"Xu, W. et al. Histone deacetylase inhibitors upregulate Snail via Smad2\/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells. Cancer Lett. 420, 1\u201313 (2018).","journal-title":"Cancer Lett."},{"key":"1221_CR39","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/ncb1762","volume":"10","author":"KJ Simpson","year":"2008","unstructured":"Simpson, K. J. et al. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat. Cell Biol. 10, 1027\u20131038 (2008).","journal-title":"Nat. Cell Biol."},{"key":"1221_CR40","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.bcp.2009.06.005","volume":"78","author":"V Hivert","year":"2009","unstructured":"Hivert, V., Pierre, J. & Raingeaud, J. Phosphorylation of human enhancer of filamentation (HEF1) on serine 369 induces its proteasomal degradation. Biochem. Pharmacol. 78, 1017\u20131025 (2009).","journal-title":"Biochem. Pharmacol."},{"key":"1221_CR41","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.1158\/0008-5472.CAN-07-1328","volume":"67","author":"GM O\u2019Neill","year":"2007","unstructured":"O\u2019Neill, G. M. et al. A new central scaffold for metastasis: parsing HEF1\/Cas-L\/NEDD9. Cancer Res 67, 8975\u20138979 (2007).","journal-title":"Cancer Res"},{"key":"1221_CR42","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.drudis.2021.11.025","volume":"27","author":"PA Quispe","year":"2022","unstructured":"Quispe, P. A., Lavecchia, M. J. & Le\u00f3n, I. E. Focal adhesion kinase inhibitors in the treatment of solid tumors: Preclinical and clinical evidence. Drug Discov. Today 27, 664\u2013674 (2022).","journal-title":"Drug Discov. Today"},{"key":"1221_CR43","doi-asserted-by":"publisher","first-page":"101312","DOI":"10.1016\/j.tranon.2021.101312","volume":"16","author":"G Shanmugam","year":"2022","unstructured":"Shanmugam, G., Rakshit, S. & Sarkar, K. HDAC inhibitors: targets for tumor therapy, immune modulation and lung diseases. Transl. Oncol. 16, 101312 (2022).","journal-title":"Transl. Oncol."},{"key":"1221_CR44","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","volume":"6","author":"Y Li","year":"2016","unstructured":"Li, Y. & Seto, E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb. Perspect. Med. 6, a026831 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1221_CR45","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/ijc.25151","volume":"127","author":"A Hayashi","year":"2010","unstructured":"Hayashi, A. et al. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int. J. Cancer 127, 1332\u20131346 (2010).","journal-title":"Int. J. Cancer"},{"key":"1221_CR46","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.urolonc.2012.06.015","volume":"31","author":"G Niegisch","year":"2013","unstructured":"Niegisch, G. et al. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol. Oncol. 31, 1770\u20131779 (2013).","journal-title":"Urol. Oncol."},{"key":"1221_CR47","doi-asserted-by":"publisher","first-page":"28021","DOI":"10.1074\/jbc.M113.498758","volume":"288","author":"C Song","year":"2013","unstructured":"Song, C., Zhu, S., Wu, C. & Kang, J. Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expression. J. Biol. Chem. 288, 28021\u201328033 (2013).","journal-title":"J. Biol. Chem."},{"key":"1221_CR48","doi-asserted-by":"publisher","first-page":"e64600","DOI":"10.1371\/journal.pone.0064600","volume":"8","author":"Y Stypula-Cyrus","year":"2013","unstructured":"Stypula-Cyrus, Y. et al. HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS One 8, e64600 (2013).","journal-title":"PLoS One"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01221-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T20:17:08Z","timestamp":1672949828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01221-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1038\/s41392-022-01221-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}